yyc g inhibitor 16

YycG inhibitor 16 is a novel YycG inhibitor, inhibiting planktonic cells of E. faecalis, including the vancomycin- or linezolid-resistant strains.

Prostaglandin G H synthase 1 inhibitor (CP 74006) is a selective D5D inhibitor with an IC(50) value of 20 nM.

PKM2 inhibitor G is a inhibitor of pyruvate kinase.

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

Protein kinase G inhibitor-2 exhibits antibacterial, antiviral, and antitumor activities.

Protein kinase G inhibitor-1 is a potent Protein kinase G inhibitor, IC50= 0.9 uM.

sEH Inhibitor-16, a potent soluble epoxide hydrolase (sEH) inhibitor, exhibits an IC50 of 2 nM. It diminishes inflammatory damage associated with cerulein-induced acute pancreatitis (AP) in mice, making it suitable for inflammation and immunology research [1].

Topoisomerase II Inhibitor 16 (compound CT3) is a selective, orally bioavailable, and irreversible inhibitor of trypanosomal topoisomerase II, possessing the ability to penetrate the brain and stabilize double-stranded DNA-enzyme cleavage complexes. It shows promise for research into Chagas disease [1].

HIV-1 inhibitor-16 (compound 7a) is a potent HIV-1 inhibitor with an EC50 of 1.3 nM against wild-type HIV-1, and exhibits inhibitory activity against HIV-1 K103N, E138K, Y181C, and L100I strains with EC50s of 5.4 nM, 9.2 nM, 22 nM, and 35 nM, respectively. It demonstrates good solubility, hepatic microsomal stability, and lacks significant CYP enzyme inhibitory activity or acute toxicity.

KRAS inhibitor-16 (compound 3-11) is a potent inhibitor of KRAS G12C (IC50: 0.457 μM) and exhibits p-ERK inhibition in MIA PaCA-2 and A549 cells with IC50s of 3.06 and 11.1 μM, respectively. KRAS inhibitor-16 has potential for study in pancreatic, colorectal, and lung cancers.

KRAS G12D Inhibitor 16 is a potent compound targeting the KRAS G12D and its mutation, exhibiting inhibitory activity with IC50 values of 0.7 nM and 0.35 μM, respectively. It is utilized in researching various malignant tumors including pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), and non-small cell lung carcinomas (NSCLC).

Compound 1, known as Carbonic anhydrase inhibitor 16, acts as a dengue protease inhibitor and also inhibits carbonic anhydrase hCA I and hCA II, with inhibitory constants (K i) of 28.5 nM and 2.2 nM, respectively [1].

Tubulin inhibitor 16 is a potent tubulin inhibitor that exhibits antiproliferative activity and cytotoxicity in HepG2 cells [1].

Mcl-1 Inhibitor 16 (Compound 9), a platinum-based mitochondrial-targeting agent, inhibits Mcl-1 and induces Bax/Bak-dependent apoptosis in cancer cells. This compound exhibits antitumor activity and may be utilized as a monotherapy or in combination with ABT-199 [1].

BRD4 Inhibitor-16 (Compound 4) is a potent inhibitor of bromodomain 4 (BRD4), whose overexpression is closely correlated with various human cancers through the regulation of histone post-translational modifications. It serves as a valuable tool for explorative studies focused on BRD4 inhibition, facilitating an enhanced comprehension of BRD4 inhibitor release-related information [1].

ATX inhibitor 16 is a potent ATX inhibitor (IC50: 0.0021 μM) that exhibits a significant anti-proliferative effect on breast cancer cells.